BUSINESS

Tivantinib Fails Japan PIII Trial for HCC: Kyowa Kirin

March 28, 2017

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Kyowa Hakko Kirin said on March 27 that the c-MET inhibitor tivantinib could not deliver a statistically significant improvement versus placebo in the primary endpoint of progression-free survival (PFS) in a Japan PIII study for the treatment of hepatocellular carcinoma…

To read the full story

Kyowa Kirin Pulls Plug on Tivantinib, Follows Daiichi Sankyo
October 10, 2017
In Yet Another Setback, Daiichi Sankyo’s Tivantinib Fails Liver Cancer PIII
February 21, 2017

BUSINESS

Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
March 6, 2026
Japan Grants First-Ever Approval to iPSC-Based Therapies
March 6, 2026
Meiji Starts Japan PIII Trial of Rezurock for CLAD
March 6, 2026
Meiji Rolls Out Rezurock in Taiwan
March 6, 2026
Toray Out-Licenses Parkinson’s Drug to Immunis
March 6, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…